RecruitingModerate-to-severe Chronic Plaque Psoriasis
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Eligible age
18–65 yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis
Sponsor: Vanda Pharmaceuticals
You may qualify if…
- ✓ Male and female subjects aged 18-65 years, inclusive
- ✓ BMI \>18 and \<40
- ✓ Minimum affected BSA of 10%
- ✓ PASI score ≥ 12
- ✓ PGA ≥ 3
- ✓ Diagnosed with moderate-to-severe plaque psoriasis
You may not qualify if…
- ✕ Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis
- ✕ History of an allergic reaction or known and/or significant sensitivity to study drug
Where it's recruiting
Source: ClinicalTrials.gov · NCT07362017 · last updated 2026-06-11